What This Document Is
This document is a case study focused on Inflammatory Bowel Disease (IBD), specifically examining a 34-year-old female patient, Mrs. Z, presenting with symptoms suggestive of an ulcerative colitis exacerbation. It’s designed for students in an Advanced Pharmacology course (NU 636) at Herzing University, as part of Unit Five coursework. The case study presents patient data – history, physical exam findings, and initial lab results – to provide a realistic clinical scenario.
Why This Document Matters
This case study is valuable for advanced nursing students preparing for advanced practice roles. It bridges the gap between theoretical pharmacological knowledge and practical clinical application. Students utilize their understanding of IBD pathophysiology, symptom presentation, and diagnostic interpretation to formulate an initial treatment plan. It’s used in a course focused on advanced pharmacology, requiring students to apply drug principles to a complex patient case.
Common Limitations or Challenges
This case study presents a *starting point* for analysis. It does not provide a definitive, exhaustive treatment protocol. Students will need to supplement this information with broader pharmacological resources and clinical guidelines. The case focuses on one patient; generalizing findings requires careful consideration of individual patient factors. It is not a substitute for comprehensive clinical experience or direct supervision.
What This Document Provides
The full document includes: a detailed patient presentation (history, symptoms, physical exam), relevant laboratory values (WBC, HgB, Het, Sodium, Potassium), a brief overview of IBD including Crohn’s disease and ulcerative colitis, and a discussion of potential medication therapies (aminosalicylates, corticosteroids, immunosuppressive agents, antibiotics, and biological agents). It also includes citations to supporting literature.
This preview *does not* include the student’s complete assessment and proposed medication regimen, nor does it contain the full discussion of pharmacological considerations for this patient. It does not provide a comprehensive review of IBD pathophysiology or treatment guidelines beyond what is stated here.
